Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
By: GlobeNewswire - 29 May 2020 | Back to overview list |
|
WALTHAM, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company approved the grant of an equity award to a new employee with a grant date of May 26, 2020, as an equity inducement award outside of the company's 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the company. The equity award was approved on April 30, 2020, in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received an option to purchase 23,216 shares of Apellis common stock. The option has an exercise price of $33.94, which is equal to the closing price of Apellis common stock on May 26, 2020, the grant date of the option. One-fourth of the shares underlying the employee option will vest on the one year anniversary of the employee’s date of employment and thereafter 1/48th of the shares underlying the employee option will vest monthly, such that the shares underlying the option granted to the employee will be fully vested on the fourth anniversary of the employee’s date of hire, subject to the employee’s continued employment with Apellis on such vesting dates. About Apellis Apellis Forward-Looking Statement Investor Contact: |
||
|
||
Copyright 2020 GlobeNewswire | Back to overview list |